LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
8.61
-0.08 (-0.92%)
Apr 29, 2026, 11:29 AM EDT - Market open
Company Description
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase.
The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026.
LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LeonaBio, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Mark Litton |
Contact Details
Address: 18706 North Creek Parkway, Suite 104 Bothell, Washington 98011 United States | |
| Phone | 425 620 8501 |
| Website | leonabio.com |
Stock Details
| Ticker Symbol | LONA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L203 |
| ISIN Number | US04746L2034 |
| Employer ID | 45-3368487 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Robert Renninger | Chief Financial Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Julie Rathbun | Head of Investor Relations |
| Mark F. Kubik M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | 424B3 | Prospectus |
| Apr 2, 2026 | 424B3 | Prospectus |
| Apr 1, 2026 | EFFECT | Notice of Effectiveness |
| Apr 1, 2026 | EFFECT | Notice of Effectiveness |
| Apr 1, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 31, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K/A | [Amend] Current report |